Related Experiment Videos
[Update on the treatment of systemic scleroderma]
Journal Des Maladies Vasculaires
|January 1, 1987
Summary
Early treatment of systemic sclerosis with colchicine or D-penicillamine may reduce skin sclerosis. Other therapies show limited efficacy or require further study for progressive systemic sclerosis management.
Area of Science:
- Rheumatology
- Dermatology
- Immunology
Context:
- Progressive systemic sclerosis (PSS) is a complex collagen disease.
- Management of PSS involves evaluating established and novel therapeutic agents.
- Recent advancements include new symptomatic therapies and renewed clinical trials.
Purpose:
- To review the efficacy and limitations of various treatments for progressive systemic sclerosis.
- To assess the potential of emerging therapies like cyclosporine A.
- To guide treatment selection for PSS based on current evidence.
Summary:
- Colchicine and D-penicillamine show potential in early PSS, primarily for cutaneous manifestations.
- Corticosteroids have limited efficacy and potential renal risks.
- Immunosuppressants, plasma exchange, and coagulation factor XIII have demonstrated variable or unproven benefits.
- Cyclosporine A's clinical utility in PSS requires further investigation.
Impact:
- Provides a comprehensive overview of PSS treatment options.
- Highlights the importance of early intervention for specific therapies.
- Identifies areas for future research in PSS management.